Moreover, calpain inhibition showed a potent protective effect in Bid-silenced cells. In conclusion, our data suggest that calpains and Bid act in a co-operative, but mutually independent manner to mediate oxaliplatin-induced apoptosis of HeLa cells.
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Introduction.
BH3-only proteins are members of the Bcl-2 family of proteins with a key role in activation of apoptosis (Youle and Strasser, 2008) . The BH3-only protein Bid has been well characterized in apoptosis triggered by ligands of the death receptors family (Kulik et al., 2001; Werner et al., 2002) ; Bid is cleaved by caspase-8 to t-Bid, which translocates to mitochondria and causes the release of caspase-activating factors from mitochondria (Korsmeyer et al., 2000; Seol et al., 2001) . Bid can also be cleaved by other proteases, including granzymes (Waterhouse et al., 2006) , cathepsins (Reiners et al., 2002; Stoka et al., 2001 ) and calpains (Chen et al., 2001; Mandic et al., 2002) , events that potentially can also lead to the release of caspase-activating factors from mitochondria.
Oxaliplatin is a DNA damaging agent belonging to a family of compounds that include Cisplatin and Carboplatin (Wang and Lippard, 2005) ; like Cisplatin it generates DNA inter-and intra-strand cross-links but the spectrum of activity and the mechanisms of action and resistance are different from cisplatin and Carboplatin (Cemazar et al., 2006; Kasparkova et al., 2008) ; the lack of cross resistance with cisplatin and Carboplatin (Rixe et al., 1996; Stordal et al., 2007) makes it a clinically important anticancer agent.
Oxaliplatin-induced apoptosis of cancer cells has been shown to be partially dependent on the BH3-only protein PUMA (Kohler et al., 2008; Wang et al., 2006) , which is activated in response to p53 during genotoxic stress. The involvement of Bid in DNA damage-induced apoptosis and genotoxic stress has recently been highlighted (Kamer et al., 2005; Kaufmann et al., 2007; Shelton et al., 2009; Zinkel et al., 2007; Zinkel et al., 2005) , albeit with controversial findings. While genetic ablation of Bid had no effects on apoptosis and cell cycle arrest in non-transformed murine cell types (Kaufmann et al., This article has not been copyedited and formatted. The final version may differ from this version. (Kamer et al., 2005; Zinkel et al., 2005) . Bid was also shown to shuttle in and out of the nucleus to regulate cell cycle arrest (Zinkel et al., 2007) . In a previous study from our laboratory, we were able to demonstrate that Bid was partially required and co-operated with PUMA in oxaliplatin-induced apoptosis of HeLa cells (Kohler et al., 2008) . However, the mechanism of Bid activation and the potential role of other proteases in mediating Bid activation remained unanswered. In this study, we characterized the role of Bid and its mechanism of activation in oxaliplatin-induced apoptosis.
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Cell culture
HeLa and HCT116 cells were grown in RPMI 1640 medium supplemented with 10%
(v/v) heat-inactivated fetal calf serum, 2 mM glutamine, 100 U/ml penicillin, and 100 mg/ml streptomycin (Sigma-Aldrich) in a humidified 5% CO 2 containing atmosphere at 37 o C. Cells were kept in logarithmic growth phase by routinely passaging them twice a week and were plated 24h prior to treatments. HeLa-DEVD cells have been described previously (Rehm et al., 2002) . Bid kd -DEVD cells were generated using similar protocols.
Colony formation assay
Cells were seeded into 24-well plates and treated as indicated. After 1h of drug exposure cells were resuspended with trypsin-EDTA, 1x10 3 cells were seeded onto 60-mm dishes
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7 and grown for 10-14 days to allow colonies to form. Medium was subsequently removed and colonies were fixed/stained with a solution containing methanol (50 %) and methylene blue (0.25 %) at room temperature for 30 min. Plates were rinsed with water and the number of colonies per plate was determined. Results are expressed as percentage of survival relative to the vehicle-treated controls (100 %).
Expression of adenoviral Bid WT and D59A mutant
HeLa Bid KD cells were infected with adenoviral vectors coding for murine tetracyclineinducible FLAG-tagged wild-type or mutant (D59A) bid, kindly provided by Dr. A.
Gross (Weizmann Institute of Science, Rehovot, Israel) (Sarig et al., 2003) . 24 h prior to infection 2 x 10 5 cells/well were seeded into 6-well plates. After washing cells twice with serum-free medium cells were infected with an MOI (multiplicity of infection) of 1000 with the reverse tet transactivator-containing virus and either the wild-type or the mutant bid-containing virus. 14 h post-infection doxycycline (1 µg/ml) was added to the medium to activate gene expression from the tet-inducible promoters. Recombinant bid protein expression was detectable after 6 h doxycycline treatment.
Generation of stable YFP-Bid-CFP cells
HeLa D98 cells were transfected with 0.6 µg of plasmid DNA (pFRET-YFP-Bid-CFP) (Onuki et al., 2002) and 6 µl of LipofectAMINE reagent (Invitrogen) per ml of serumfree culture medium at 37 °C for 3 h. For the generation of stable cell lines, transfected HeLa D98 cells were selected in the presence of 1 mg/ml G418 for 2 weeks, and fluorescent clones were enriched. Expression of YFP-Bid-CFP was verified by immunoblotting using antibodies against GFP (data not shown). West Pico Chemiluminescent Substrate (Pierce) and imaged using a FujiFilm LAS-3000 imaging system (Fuji).
SDS-PAGE and Western blotting
Determination of caspase-3-like protease activity
Cells were lysed in 200 µl lysis buffer (10 mmol/l HEPES, pH 7.4, 42 mmol/l KCl, 5 mmol/l MgCl2, 1 mmol/l phenylmethylsulphonyl fluoride, 0.1 mmol/l EDTA, 0.1 mmol/l EGTA, 1 mmol/l dithiothreitol, 1 µg/ml pepstatin A, 1 µg/ml leupeptin, 5 µg/ml aprotinin, 0.5% CHAPS). Fifty microlitres of this lysate were added to 150 µl reaction buffer (25 mmol/l HEPES, 1 mmol/l EDTA, 0.1% CHAPS, 10% sucrose, 3 mmol/l dithiothreitol, pH 7.5 and 10 µmol/l of the caspase substrate Ac-DEVD-AMC). Cleavage
Confocal imaging analysis of YFP-Bid-CFP translocation and FRET disruption
HeLa Bcl-2 over-expressing cells transiently transfected with the YFP-Bid-CFP FRET probe were cultivated in 35mm glass bottom dishes (Wilcow BV, Amsterdam, The Netherlands) in 2 ml of medium overnight to let them attach firmly. Cells were treated with Oxaliplatin (30 µg/ml) for 24h and equilibrated with 30 nM TMRM in RPMI 1640 medium (Sigma-Aldrich) supplemented with penicillin (100 U/ml), streptomycin (100 µg/ml) and 10% fetal calf serum, buffered with N-2-hydroxyl piperazine-N'-2-ethane sulfonic acid (HEPES, 10 mM; pH 7.4), covered with mineral oil, and placed in a heated (37 °C) incubation chamber that was mounted on the microscope stage. Images were collected through a Zeiss LSM 510 meta confocal microscope equipped with a 488 nm argon ion laser, 543 nm diode laser and a 405 nm diode laser set up as previously described (Ward et al., 2006) . FRET disruption was analysed as described (Ward et al., 2006) .
Statistics
Data are given as means ± SD or SEM. For statistical comparison, t-test or one-way
ANOVA followed by Tukey test were employed using SPSS software (SPSS GmbH
This article has not been copyedited and formatted. The final version may differ from this version. Software, Munich, Germany). P-values smaller than 0.05 were considered to be statistically significant.
Results
Bid has a central role in oxaliplatin-induced apoptosis
To analyze with Etoposide also showed a reduced caspase-3 processing and PARP cleavage ( Fig   2A) .
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Oxaliplatin-induced Bid activation is not mediated by caspase-8
To investigate the potential involvement of caspase -8 and -10 in Oxaliplatin-mediated Bid activation, HeLa Bid kd cells were infected with an adenoviral vector inducibly expressing either FLAG-tagged wild type Bid (Bid wt) or Bid D59A (Sarig et al., 2003) ( Fig. 3A) , a mutant where the aspartic acid within the caspase cleavage motif at position 59 has been mutated to alanine, thus abolishing proteolytic cleavage by caspase-8 and -10. Western Blot detection of Bid revealed that expression levels of adenovirally expressed Bid after viral transduction at 1000 multiplicity of infection (MOI) in the presence of doxycycline in the Bid knockdown background were comparable to expression levels of endogenous Bid in HeLa control cells (Fig. 3A) . Additional Western Blot experiments did not detect differences in the kinetics of TRAIL-induced procaspase-8 activation in HeLa cells expressing either Bid wt or Bid D59A (Fig. 3B ).
Following transduction with Bid wt, we observed cleavage of full-length Bid and
This article has not been copyedited and formatted. The final version may differ from this version. 14 processing of caspase-8, -9 and -3 to their active forms, all of which were inhibited by the pan-caspase inhibitor zVAD (Fig. 3B) . The Bid D59A mutation abolished processing of Bid to tBid after TRAIL treatment and this lack of proteolytic activation was associated with a pronounced decrease of caspase-9 and caspase-3 induction in the Bid knockdown background (Fig. 3B ).
To analyze whether cleavage of Bid by caspase-8 or -10 was required for apoptosis induced by Oxaliplatin, we performed a time course experiment (6 to 32 h) in which we analyzed the effects of the D59A mutation on Oxaliplatin-induced activation of procaspases -8, -9 and -3 and on processing of Bid (Fig. 4) . Our Western Blots indicated that doxycycline increased protein levels of full-length Bid wt and Bid D59A in a timedependent manner, whereas only minor levels of processed t-Bid could be observed in both cases, even at 32 h after Oxaliplatin treatment (Fig. 4) . Interestingly, the kinetics of Bid cleavage and activation of procaspases -9 and -3 were not affected by the Bid mutant, indicating that Oxaliplatin-mediated activation of Bid and subsequent activation of the intrinsic pathway was independent of caspase-8 or -10.
Oxaliplatin-induced activation of caspases occurs downstream of mitochondria engagement
To further investigate the extent of effector caspase activation following oxaliplatin treatment, control and HeLa Bid kd cells were stably transfected with a construct encoding a CFP-DEVD-YFP caspase-3 / -7 substrate FRET probe (Rehm et al., 2002) .
We employed flow cytometry techniques to simultaneously measure effector caspase activity and mitochondrial dysfunction by analyzing depolarization of mitochondrial This article has not been copyedited and formatted. The final version may differ from this version. membrane potentials (∆ψ M ) with tetra-methyl-rhodamine-methyl ester (TMRM). To prevent potential postmitochondrial feedback mechanisms, we also employed the pancaspase inhibitor zVAD-fmk. In this experimental setting, effector caspase activation and mitochondrial depolarization induced by the death receptor ligand TRAIL were both inhibited by zVAD (Fig. 5A, C) , confirming that caspase activation occurs upstream of mitochondrial outer membrane permeabilization (MOMP) in death receptor-mediated apoptosis. In contrast, zVAD was able to uncouple mitochondrial dysfunction from effector caspase activation when the Bid-independent apoptotic stimulus STS was applied, as zVAD did not prevent mitochondrial depolarization in this case (Fig. 5D ).
These data indicated that STS-triggered caspase activation occurred downstream of MOMP. Surprisingly, similar experiments performed with oxaliplatin showed a profile comparable to that observed after treatment with STS ( Fig. 5B, E) . Knockdown of Bid significantly reduced the percentage of cells displaying Annexin-V staining (Fig. 5F ), depolarized mitochondria and effector caspase activation ( Supplementary Fig. 1 ). In a separate approach, we performed a Western Blot analysis of caspase-2, -3, -8 and -9 processing after treatment with oxaliplatin in HeLa control cells vs. HeLa cells overexpressing Bcl-2 (Fig. 6A) . In control cells, all of these caspases were processed in the apoptotic cascade, albeit these experiments could not clearly resolve in what order they were activated (Fig. 6B ). In the HeLa Bcl-2 cells, oxaliplatin-triggered activation of caspase-2 and -8 was abrogated, suggesting that both caspases require a caspase-3-dependent feedback loop for their activation in response to oxaliplatin. Partial cleavage of Bid to t-Bid which was observed after oxaliplatin treatment of HeLa control cells (Fig.   6B ) was completely blocked by over-expression of Bcl-2 (Fig. 6C ).
This article has not been copyedited and formatted. The final version may differ from this version. processing of m-, µ-calpain and Bid cleavage (Fig. 7A) as well as reduced processing of caspase-2, -3, -8, and -9 (Fig. 7B ) in the presence of calpeptin (see also Suppl. Fig. 1 ).
The results demonstrated that calpain activation was involved in oxaliplatin-induced apoptosis, and that calpains are activated upstream of mitochondria engagement.
These studies were further confirmed by flow cytometry studies. Calpeptin did not prevent mitochondrial membrane depolarization and effector caspase activation induced by TRAIL or STS as analyzed by flow cytometry, thereby confirming its specificity (Fig.   8A, B) ; however, calpeptin significantly impaired effector caspase activation, mitochondrial dysfunction and apoptosis after treatment of HeLa control cells with oxaliplatin ( Fig. 8C, D preserved in HeLa Bid kd cells (Fig. 8C , D, E, F; Suppl. Figure 1) , suggesting a Bidindependent role for calpains in Oxaliplatin-induced apoptosis. Similar to its effect in Oxaliplatin-induced apoptosis, calpain inhibition also significantly reduced the activation of effector caspases in control and Bid-silenced HeLa cells exposed to Etoposide (Fig. 9) .
Full-length Bid translocates to the mitochondria and nucleus following oxaliplatin treatment and its translocation is not affected by caspases or calpain inhibition
Although our data obtained so far had suggested that Bid plays an important role in
Oxaliplatin-induced apoptosis, we also had observed that Bid cleavage occurs largely signal, and t-Bid-CFP, but not YFP-cBid accumulated at mitochondria (Fig. 10A) . In
Oxaliplatin-treated cells, the FRET signal remained intact, indicating that Bid was not proteolytically processed. Interestingly, there was also a pronounced redistribution of the FRET, CFP and YFP signals to the mitochondria, strongly suggesting that uncleaved, full-length YFP-Bid-CFP translocated to mitochondria following Oxaliplatin treatment (Fig 10A) . Quantitative analysis confirmed that ~ 50 percent of the cells revealed a mitochondrial localization of YFP-Bid-CFP after treatment with Oxaliplatin (Fig. 10C ).
There were no major changes in the number of cells displaying mitochondrial localization of full-length Bid when cells were co-treated with Oxaliplatin in combination with calpeptin, zVAD or calpeptin plus zVAD (Fig. 10C ). Additional flow cytometry experiments of YFP-Bid-CFP cleavage in HeLa Bid kd cells supported the absence of Bid cleavage prior to mitochondrial depolarization in response to Oxaliplatin (Suppl. Fig.   2 ). Interestingly, we also observed a significant translocation of CFP-Bid-YFP to the nuclear compartment during Oxaliplatin-induced apoptosis (Fig. 10B, C) , as reported in previous studies (Kamer et al., 2005; Zinkel et al., 2005) .
Discussion.
In this study, we characterized the role of the BH3-only protein Bid and the mechanisms before treatement with CHX (1 µg/ml) in combination with recombinant TRAIL for the indicated times; lysates were subjected to Western blotting with a monoclonal caspase-8, a polyclonal caspase-9, a polyclonal caspase-3 antibody and a monoclonal β-actin antibody. were preincubated with doxycycline (1 µg/ml) for 16 h before treatment with oxaliplatin for the This article has not been copyedited and formatted. The final version may differ from this version. polyclonal caspase-9, a polyclonal caspase-3 antibody and a monoclonal β-actin antibody. 
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